Signaling Pathways
-
B2173 CP-673451Target: PDGFRSummary: PDGFRα/β inhibitor,potent and selective
-
A3750 Regorafenib hydrochlorideTarget: Raf|VEGFR|PDGFR|c-Kit|c-RETSummary: Tyrosine kinase inhibitor
-
A3870 TG 100801Target: VEGFR|FGFR|Src|Fyn kinaseSummary: Multi-kinase inhibitor
-
A3009 Sorafenib2 CitationTarget: Raf|VEGFRSummary: Raf kinases and tyrosine kinases inhibitor
-
A3022 Pazopanib (GW-786034)Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFRSummary: VEGFR/PDGFR/FGFR inhibitor
-
C3342 MAZ51Target: VEGFRSummary: VEGFR3 antagonist
-
B5835 AZD2932Target: FLT3|VEGFR|PDGFR|c-KitSummary: inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit
-
B5864 Fruquintinib(HMPL-013)Target: VEGFRSummary: Potent and selective inhibitor of VEGFR 1, 2, 3
-
B5953 Dovitinib (TKI258) LactateTarget: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFRSummary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).